Blood, Breath Markers May Tell Lung Diseases Apart

Adults with fibrotic lung scarring could eventually get a noninvasive test, though this early study involved just 101 people.

Updated on Nov. 2, 2026 in Asthma

Clear glass vessel of pale amber liquid on a clean laboratory bench under soft daylight, with a blurred, uncluttered lab background.
Researchers presented early findings at the CHEST 2026 Annual Meeting suggesting blood and breath molecular markers could help tell apart two forms of fibrotic lung disease. AI Illustration. Upload story photo >

Researchers presented findings at the CHEST 2026 Annual Meeting showing that sphingolipid profiles in blood plasma and exhaled breath condensate can distinguish idiopathic pulmonary fibrosis (IPF) from fibrotic hypersensitivity pneumonitis (f-HP), two forms of fibrotic interstitial lung disease (ILD). The work is early-stage and drew on a small study of 101 participants.

Why it matters

Fibrotic ILD is often hard to tell apart on clinical grounds, and the current diagnostic path can be slow and invasive. A noninvasive blood or breath-based marker that separates these conditions could eventually help clinicians sort patients more quickly, which matters most for people with lung scarring who are waiting for a clear diagnosis.

This was a single-institution study of 101 adults, including 33 with IPF, 40 with fibrotic hypersensitivity pneumonitis, and 28 healthy controls, with diagnoses confirmed by multidisciplinary ILD conference review. Results are preliminary: the findings were presented at a conference and have not been described as peer-reviewed publication in this report.

The players

CHEST

The American College of Chest Physicians, a professional society that runs the CHEST Annual Meeting and advances care for lung and breathing disorders.

Virginia Commonwealth University

A public research university whose institutional review board approved the study and whose researchers conducted the work.

The details

Sphingolipids are fats that help build and signal within cell membranes, and their levels can shift when tissue is injured and scarred. Using high-performance liquid chromatography-tandem mass spectrometry, the researchers measured a targeted panel of these molecules in patients' plasma and exhaled breath condensate, a fluid captured from breath. Clinical measures, including pulmonary function testing and GAP indices, were pulled from electronic medical records to compare against the molecular profiles. The samples came from an institutional biorepository, and the study was approved by Virginia Commonwealth University's institutional review board.

Timeline

  1. October 12, 2026: CHEST issued a news release on the sphingolipid profiling work.

  2. October 18-21, 2026: CHEST 2026 Annual Meeting was held in Phoenix, Arizona.

  3. October 19, 2026: The sphingolipid findings were presented during the ILD: Clinical Roundup session.

Health Landscape

Diagnosing fibrotic ILD usually depends on imaging, lung function tests, and sometimes tissue sampling, which can be invasive for patients. Researchers are increasingly exploring blood and breath-based markers as a way to speed up and simplify that process.

If you have been diagnosed with a fibrotic lung condition or are being evaluated for one, these findings are not yet something you can request. They do suggest that noninvasive tests may eventually supplement current workups, so it is reasonable to ask your pulmonologist which diagnostic steps are most useful for your situation.

The takeaway

Blood and breath tests may one day help separate fibrotic lung diseases that look similar on imaging, but this work is early and small. If you have lung scarring, the practical step is to discuss your full diagnostic plan with a pulmonologist.

Further reading

For more on lung conditions, see our Asthma coverage.

Source note: This article includes information reported by Ajmc.